TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Early Nutrient Intake on Growth and Body Composition
Brief Summary: The primary objective of the study is to compare the growth of infants fed standard infant formula with infants fed a reduced calorie and protein formula.


Options:
A: Arm Label: Breast Fed reference group; Type: N/A; Interventions: N/A | Arm Label: Infant formula - protein level 1; Type: N/A; Interventions: N/A | Arm Label: Infant formula - protein level 2; Type: N/A; Interventions: N/A
B: Arm Label: Human Milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Human Milk | Arm Label: Milk based standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Milk based standard infant formula | Arm Label: Milk based investigational infant formula; Type: EXPERIMENTAL; Interventions: Other: Investigational infant formula | Intervention Type: OTHER; Name: Human Milk; Assigned to Arm(s): Human Milk | Intervention Type: OTHER; Name: Investigational infant formula; Assigned to Arm(s): Milk based investigational infant formula | Intervention Type: OTHER; Name: Milk based standard infant formula; Assigned to Arm(s): Milk based standard infant formula
C: Arm Label: Previously marketed infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Previously marketed infant formula | Arm Label: Previously marketed formula using a similar protein; Type: EXPERIMENTAL; Interventions: Other: Previously marketed formula using a similar protein | Intervention Type: OTHER; Name: Previously marketed infant formula; Assigned to Arm(s): Previously marketed infant formula | Intervention Type: OTHER; Name: Previously marketed formula using a similar protein; Assigned to Arm(s): Previously marketed formula using a similar protein
D: Arm Label: IF-VLP (very low protein); Type: EXPERIMENTAL; Interventions: Other: Infant formula | Arm Label: IF-LP (low protein); Type: OTHER; Interventions: Other: Infant formula | Arm Label: IF-CSP (control standard protein); Type: OTHER; Interventions: Other: Infant formula | Arm Label: HM (human milk); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): IF-CSP (control standard protein), IF-LP (low protein), IF-VLP (very low protein)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study on a Nordic Lifestyle Intervention Trial Investigating the Effect of Vigorous Activity and Intake of Whole Grain Rye on Cancer Progression, Insulin Sensitivity and Inflammation Among Men With Early Stage Prostate Cancer.
Brief Summary: PURPOSE:

To evaluate the feasibility of a future Nordic intervention trial, including vigorous activity and a high intake of whole grain rye, among prostate cancer patients on active surveillance.

Additionally, to investigate effects of the lifestyle intervention according to cancer progression, the metabolic profile, inflammation and quality of life among prostate cancer patients on active surveillance.


Options:
A: Arm Label: Exercise and whole grain rye; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Whole grain rye, Behavioral: Recommendations | Arm Label: No prescriptions; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Recommendations | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise and whole grain rye | Intervention Type: BEHAVIORAL; Name: Whole grain rye; Assigned to Arm(s): Exercise and whole grain rye | Intervention Type: BEHAVIORAL; Name: Recommendations; Assigned to Arm(s): Exercise and whole grain rye, No prescriptions
B: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials
C: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
D: Arm Label: Exercise Intervention Program (EIP); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Care-Management-Phone-Calls | Arm Label: Care-Management-Phone-Calls (CMPC); Type: ACTIVE_COMPARATOR; Interventions: Other: Care-Management-Phone-Calls | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Program (EIP) | Intervention Type: OTHER; Name: Care-Management-Phone-Calls; Assigned to Arm(s): Care-Management-Phone-Calls (CMPC), Exercise Intervention Program (EIP)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial of the Collaborative Assessment and Management of Suicidality Versus Enhanced Care as Usual for Suicidal Soldiers
Brief Summary: This is a randomized controlled trial comparing the use of new clinical intervention (the "Collaborative Assessment and Management of Suicidality--CAMS") versus enhanced care as usual for suicidal Soldiers who are seen at outpatient mental health clinics at Ft. Stewart GA.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Psychiatric Management | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Intervention Type: BEHAVIORAL; Name: General Psychiatric Management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): 2
B: Arm Label: 20 weeks skills group; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Skills Training; Assigned to Arm(s): 20 weeks skills group
C: Arm Label: Zero Suicide Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Usual Care | Arm Label: Zero Suicide Usual Care + ASSIP; Type: EXPERIMENTAL; Interventions: Behavioral: Attempted Suicide Short Intervention Program | Intervention Type: BEHAVIORAL; Name: Attempted Suicide Short Intervention Program; Assigned to Arm(s): Zero Suicide Usual Care + ASSIP | Intervention Type: BEHAVIORAL; Name: Zero Suicide Usual Care; Assigned to Arm(s): Zero Suicide Usual Care
D: Arm Label: CAMS--Collaborative Driver-Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: The Collaborative Assessment and Management of Suicidality | Arm Label: Enhanced Care as Usual--E-CAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Care as Usual | Intervention Type: BEHAVIORAL; Name: The Collaborative Assessment and Management of Suicidality; Assigned to Arm(s): CAMS--Collaborative Driver-Treatment | Intervention Type: BEHAVIORAL; Name: Enhanced Care as Usual; Assigned to Arm(s): Enhanced Care as Usual--E-CAU

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Shang Ring With Conventional Surgical Methods: A Randomized Controlled Trial
Brief Summary: This is a randomized control trial of 400 adult male circumcision procedures with a one to one ratio between Shang Ring and the in-country standard surgical technique (forceps guided in Kenya and dorsal slit in Zambia).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Shang Ring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Male circumcision | Intervention Type: DEVICE; Name: Shang Ring; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Male circumcision; Assigned to Arm(s): 2
B: Arm Label: Unicirc with tissue adhesive; Type: EXPERIMENTAL; Interventions: Procedure: Unicirc with tissue adhesive | Arm Label: Open Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Surgical | Intervention Type: PROCEDURE; Name: Unicirc with tissue adhesive; Assigned to Arm(s): Unicirc with tissue adhesive | Intervention Type: PROCEDURE; Name: Open Surgical; Assigned to Arm(s): Open Surgical
C: Intervention Type: PROCEDURE; Name: Adult male circumcision; Assigned to Arm(s): N/A
D: Arm Label: PrePex™; Type: EXPERIMENTAL; Interventions: Device: PrePex™ device for adult male circumcision | Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical circumcision | Intervention Type: DEVICE; Name: PrePex™ device for adult male circumcision; Assigned to Arm(s): PrePex™ | Intervention Type: PROCEDURE; Name: Surgical circumcision; Assigned to Arm(s): Surgical

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Course of Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Brief Summary: Intralesional injection of antimony has been used for L major from Iran with a modest cure rate \[56%: Asilian 2004\]. However, this therapeutic approach has been used for L braziliensis from Brazil, with an attractive cure rate after 3 months of 80% \[Oliveira-Neto 1997\]. Because intralesional Sb injections is the local therapy with the best reported cure rate for South American L braziliensis disease, the species that causes disease in Bolivia, this pilot study of local therapy for bolivian L braziliensis disease will evaluate intralesional Sb therapy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: meglumine antimoniate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: controlled nitric oxide releasing patch | Intervention Type: DRUG; Name: controlled nitric oxide releasing patch; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: meglumine antimoniate; Assigned to Arm(s): 1
B: Arm Label: Intralesional antimony; Type: EXPERIMENTAL; Interventions: Drug: pentavalent antimony | Arm Label: Cryotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: cryotherapy | Arm Label: Topical cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo cream | Intervention Type: DRUG; Name: pentavalent antimony; Assigned to Arm(s): Intralesional antimony | Intervention Type: PROCEDURE; Name: cryotherapy; Assigned to Arm(s): Cryotherapy | Intervention Type: DRUG; Name: placebo cream; Assigned to Arm(s): Topical cream
C: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment
D: Arm Label: Group 1 - Paromomycin cream; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Sulfate | Arm Label: Group 2. Local Injectable Pentamidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentamidine Isethionate | Arm Label: Group 3. Vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Paromomycin Sulfate; Assigned to Arm(s): Group 1 - Paromomycin cream | Intervention Type: DRUG; Name: Pentamidine Isethionate; Assigned to Arm(s): Group 2. Local Injectable Pentamidine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 3. Vehicle control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study
Brief Summary: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.


Options:
A: Arm Label: Treatment sequence A, B; Type: EXPERIMENTAL; Interventions: Drug: pitavastatin, Drug: placebo | Arm Label: Treatment sequence B, A; Type: EXPERIMENTAL; Interventions: Drug: pitavastatin, Drug: placebo | Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): Treatment sequence A, B, Treatment sequence B, A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Treatment sequence A, B, Treatment sequence B, A
B: Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): N/A
C: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 40 mg QD
D: Arm Label: Pitavastatin 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Arm Label: Pitavastatin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 2 mg, Pitavastatin 4 mg | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Simvastatin 20 mg, Simvastatin 40 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study
Brief Summary: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.


Options:
A: Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: Lisinopril | Arm Label: Lisinopril Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril | Arm Label: Pravastatin; Type: EXPERIMENTAL; Interventions: Drug: Pravastatin | Arm Label: Pravastatin placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin, Pravastatin placebo | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril, Lisinopril Placebo
B: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 40 mg QD
C: Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled, Double Blinded, Clinical Trial: 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children
Brief Summary: The primary objective of this study is to compare the mean serum sodium after 48 hours of therapy with either 0.45% NaCl/dextrose 5% or 0.9% NaCl/dextrose 5%, in critically ill children requiring IV maintenance fluid administration.


Options:
A: Arm Label: Isotonic fluid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotonic fluid | Arm Label: Fluid restriction group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypotonic fluid | Arm Label: Hypotonic fluid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypotonic fluid | Intervention Type: DRUG; Name: Isotonic fluid; Assigned to Arm(s): Isotonic fluid group | Intervention Type: DRUG; Name: Hypotonic fluid; Assigned to Arm(s): Fluid restriction group | Intervention Type: DRUG; Name: Hypotonic fluid; Assigned to Arm(s): Hypotonic fluid group
B: Arm Label: 0.9% NaCl; Type: EXPERIMENTAL; Interventions: Drug: 0.9% NaCl | Arm Label: 0.45% NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.45%NaCl | Intervention Type: DRUG; Name: 0.9% NaCl; Assigned to Arm(s): 0.9% NaCl | Intervention Type: DRUG; Name: 0.45%NaCl; Assigned to Arm(s): 0.45% NaCl
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 0.9% saline in 5% dextrose (intravenous) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.45% saline in 5% dextrose (intravenous) | Intervention Type: DRUG; Name: 0.9% saline in 5% dextrose (intravenous); Assigned to Arm(s): A | Intervention Type: DRUG; Name: 0.45% saline in 5% dextrose (intravenous); Assigned to Arm(s): B
D: Arm Label: Hypotonic; Type: ACTIVE_COMPARATOR; Interventions: Drug: hypotonic | Arm Label: Isotonic; Type: EXPERIMENTAL; Interventions: Drug: isotonic | Intervention Type: DRUG; Name: hypotonic; Assigned to Arm(s): Hypotonic | Intervention Type: DRUG; Name: isotonic; Assigned to Arm(s): Isotonic

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutritional Status of Iodine in the Pregnant Population of Catalonia: a Study of Dietary Habits and Urinary Iodine
Brief Summary: The purpose of this study is to assess the effectiveness of individual education versus group education about dietary habits and iodine supplementation to decrease iodine deficiency in pregnant women


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ACOG education pamphlet on preeclampsia | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Preeclampsia education tool | Intervention Type: BEHAVIORAL; Name: ACOG education pamphlet on preeclampsia; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Preeclampsia education tool; Assigned to Arm(s): 3
B: Intervention Type: BEHAVIORAL; Name: Family Spirit curriculum; Assigned to Arm(s): N/A
C: Arm Label: Group Education; Type: EXPERIMENTAL; Interventions: Other: Group Education | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Group Education; Assigned to Arm(s): Group Education
D: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).
Brief Summary: Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency. Sometimes patients do not have a satisfactory response, and may benefit from trying an alternative oral medicine. Fesoterodine is related to tolterodine by producing the same active substance that acts on the bladder, but potentially at higher and more effective levels. So, a patient who has a poor response to tolterodine may still obtain a good response to fesoterodine. This study will help find out if this is what happens.


Options:
A: Intervention Type: DRUG; Name: ONO-8025 (KRP-197); Assigned to Arm(s): N/A
B: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine 8 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine 8 mg; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Anticholinergic medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticholinergic medications | Arm Label: Hypnotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hypnotherapy | Intervention Type: DRUG; Name: Anticholinergic medications; Assigned to Arm(s): Anticholinergic medications | Intervention Type: BEHAVIORAL; Name: Hypnotherapy; Assigned to Arm(s): Hypnotherapy
D: Arm Label: Tolterodine ER; Type: EXPERIMENTAL; Interventions: Drug: Tolterodine ER | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): Tolterodine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.
Brief Summary: This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to assess if the higher dose reduces the overall effect of overactive bladder on the subject's daily life more than the lower dose. The study also assesses the side effects and safety of the two doses.


Options:
A: Arm Label: Fesoterodine 8mg; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine 8mg | Arm Label: Fesoterodine 4mg; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine 4mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine 8mg; Assigned to Arm(s): Fesoterodine 8mg | Intervention Type: DRUG; Name: Fesoterodine 4mg; Assigned to Arm(s): Fesoterodine 4mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: ONO-8025 (KRP-197); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tolterodine ER 4mg QD; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: solifenacin | Arm Label: Solifenacin 10 mg; Type: EXPERIMENTAL; Interventions: Drug: solifenacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Solifenacin 5 mg | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 5 mg

Answer: A